Exelixis Inc
(NAS:EXEL)
$
35.81
-0.04 (-0.11%)
Market Cap: 10.23 Bil
Enterprise Value: 9.24 Bil
PE Ratio: 22.96
PB Ratio: 4.50
GF Score: 91/100 Exelixis Inc at Guggenheim Partners Oncology Day Transcript
Feb 14, 2019 / 02:00PM GMT
Release Date Price:
$22.3
(+1.13%)
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Are we good? Okay. Good morning. My name is Michael Schmidt. I'm one of the biotech analysts at Guggenheim Securities. It is my great pleasure to welcome the first company this morning, Exelixis.
With us today, we have Michael Morrissey, President and CEO. Michael, welcome. Thanks so much for joining us.
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
Good morning.
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
And before we kick in into some very difficult Q&A...
Michael M. Morrissey
Exelixis, Inc. - CEO, President & Director
There you go. Give me some...
Michael Werner Schmidt
Guggenheim Securities, LLC, Research Division - Senior Analyst & Senior MD
Why don't you just give some very brief overview of the story, just to
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot